XETRA - Delayed Quote EUR

DexCom, Inc. (DC4.DE)

71.58
+0.52
+(0.73%)
At close: June 13 at 5:35:43 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Kevin Ronald Sayer Executive Chairman & CEO 1.12M -- 1958
Mr. Jacob Steven Leach President & COO 599.89k -- 1978
Mr. Jereme M. Sylvain CPA Executive VP, CFO & Chief Accounting Officer 538.3k -- 1980
Mr. Michael Jon Brown Executive VP & Chief Legal Officer 525.56k -- 1971
Ms. Sadie M. Stern Executive VP & Chief Human Resources Officer 476.74k -- 1975
Mr. Girish Naganathan Executive VP & CTO 366.9k -- 1978
Mr. Sean Christensen Vice President of Finance and Investor Relations -- -- --
Mr. Matthew Dolan Executive Vice President of Strategy & Corporate Development -- -- 1981
Ms. Leverne Marsh Executive Vice President of Marketing -- -- --
Mr. Donald M. Abbey Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs 663.67k -- 1967

DexCom, Inc.

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200 https://www.dexcom.com/global
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
10,200

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.’s ISS Governance QualityScore as of June 1, 2025 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 23, 2025 at 10:59 AM UTC - July 28, 2025 at 12:00 PM UTC

DexCom, Inc. Earnings Date

Recent Events

Related Tickers